SLNO
NASDAQ
US
Soleno Therapeutics, Inc. - Common Stock
$39.49
▲ +$2.50
(+6.76%)
Vol 3.6M
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$2.5B
ROE
-25.9%
Margin
21.6%
D/E
10.08
Beta
-3.27
52W
$42–$90
Wall Street Consensus
19 analysts · Apr 20267
Strong Buy
11
Buy
1
Hold
0
Sell
0
Strong Sell
94.7%
Buy Rating
Price Chart
Similar Stocks
ADMA
ADMA Biologics Inc
P/E 20.7
$4.3B
RARE
Ultragenyx Pharmaceutical Inc
$2.2B
TYRA
Tyra Biosciences Inc
$1.4B
CLDX
Celldex Therapeutics Inc
$1.8B
AGIO
Agios Pharmaceuticals Inc
$1.6B
STOK
Stoke Therapeutics Inc
P/E 44.2
$1.8B
VRDN
Viridian Therapeutics Inc
$3.0B
CAPR
Capricor Therapeutics Inc
$1.6B
SION
Sionna Therapeutics Inc
$1.8B
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $0.73 | $0.80 | +$0.08 |
| Sep 2025 | $0.05 | $0.47 | +$0.42 |
| Jun 2025 | $-0.47 | $-0.09 | +$0.38 |
| Mar 2025 | $-0.95 | $-0.95 | $0.00 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -73.7% | -73.7% | -73.7% | -73.7% | -25.9% | -25.9% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -14.4% | -14.4% | -14.4% | -14.4% | 21.6% | 21.6% |
| Gross Margin | 97.9% | 97.9% | 97.9% | 97.9% | 98.1% | 98.1% |
| D/E Ratio | 20.76 | 20.76 | 20.76 | 20.76 | 10.08 | 10.08 |
| Current Ratio | 15.13 | 15.13 | 15.13 | 15.13 | 16.08 | 16.08 |
Key Ratios
ROA (TTM)
-19.8%
P/S (TTM)
25.20
P/B
7.9
EPS (TTM)
$-1.84
CF/Share
$-3.15
52W High
$90.32
52W Low
$41.50
$41.50
52-Week Range
$90.32
How does SLNO compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
SLNO valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
25.2
▲
96%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
7.9
▲
221%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
SLNO profitability vs Biotechnology peers
ROE
-25.9%
▲
62%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
21.6%
▲
108%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
98.1%
▲
25%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-19.8%
▲
58%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
SLNO financial health vs Biotechnology peers
D/E ratio
10.1
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
16.1
▲
262%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
-3.3
▼
437%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
SLNO fundamentals radar
SLNO
Peer median
Industry
SLNO profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
SLNO vs peers: key metrics
Latest News
No related news yet